Tech Company Financing Transactions
Incyclix Bio Funding Round
Boxer Capital, Eshelman Ventures and private investors participated in a $30 million Series B funding round for Incyclix Bio. The financing was announced on 3/31/2022.
Transaction Overview
Company Name
Announced On
3/31/2022
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the clinical development of Incyclix Bio's lead compound, INX-315, a novel, potent and selective CDK2 inhibitor with compelling preclinical efficacy and safety data. Incyclix Bio expects to initiate a proof-of-concept Phase 1/2 study of INX-315 in CDK4/6-resistant and Cyclin E-overexpressed cancers, including breast and ovarian cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 Park Offices Drive Suite 355 Research
Triangle Park, NC 27709
USA
Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
Developer of small molecule inhibitors of cyclin-dependent kinases (CDKs) intended to provide treatment for patients with advanced and resistant cancers. The company's inhibitors help to achieve the potent and selective inhibition of elusive CDK targets, enabling pharmaceutical companies and medical practitioners with novel drugs to help and improve the treatment of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Roberts
Co-Founder
Jay Strum
Browse more venture capital transactions:
Prev: 3/31/2022: Reema Health venture capital transaction
Next: 3/31/2022: Pacto venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs